اين پنجره صرفا براي تامين منابع مالي وبلاگ ايجاد شده است !

با کليک روي دکمه × یا دکمه بستن آنرا ببنديد

به وبلاگ من خوش آمديد

صفحه اصلی | مرندی | فروشگاه | سایت مپ

profile 1014

profile 1014

profile 1014

profile 1014

تو سایت ما چیزی پیدا نشد ، ببینیم برادر ، گوگل چی میگه !


profile 1014

profile 1014

profile 1014

profile 1014

profile 1014

First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung ...

www.nejm.org/doi/full/10.1056/NEJMoa1408440
4 Dec 2014 ... ... with previously untreated advanced ALK-positive NSCLC. (Funded by Pfizer;
PROFILE 1014 ClinicalTrials.gov number, NCT01154140.).

A Clinical Trial Testing The Efficacy Of Crizotinib Versus Standard ...

https://clinicaltrials.gov/ct2/show/NCT01154140
... Standard Chemotherapy Pemetrexed Plus Cisplatin Or Carboplatin In Patients
With ALK Positive Non Squamous Cancer Of The Lung (PROFILE 1014).

Intracranial Efficacy of Crizotinib Versus Chemotherapy in Patients ...

ascopubs.org/doi/abs/10.1200/jco.2015.63.5888
Intracranial Efficacy of Crizotinib Versus Chemotherapy in Patients With
Advanced ALK-Positive Non–Small-Cell Lung Cancer: Results From PROFILE
1014.

First-line crizotinib versus chemotherapy in ALK-positive lung cancer.

https://www.ncbi.nlm.nih.gov/pubmed/25470694
4 Dec 2014 ... ... Mekhail T, Felip E, Cappuzzo F, Paolini J, Usari T, Iyer S, Reisman A, Wilner
KD, Tursi J, Blackhall F; PROFILE 1014 Investigators.

PROFILE 1014: lessons for the new era of lung cancer ... - NCBI - NIH

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4630507/
23 Apr 2015 ... PROFILE 1014 compared crizotinib to up to six cycles of standard platinum-
pemetrexed chemotherapy as the first line treatment of advanced ...

Crizotinib as first line therapy for advanced ALK-positive non-small ...

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4630528/
In the PROFILE 1014 trial published by Solomon et al. (8), the investigators
examined the effect of crizotinib compared with standard platinum-based doublet
 ...

Meeting Library | First-line crizotinib versus pemetrexed<span ...

meetinglibrary.asco.org/content/129938-144
... in patients (pts) with advanced ALK-positive non-squamous non-small cell lung
cancer (NSCLC): results of a phase III study (PROFILE 1014). Presented ...

Crizotinib Tops Chemo for ALK-Positive NSCLC With Brain ...

www.cancernetwork.com/.../crizotinib-tops-chemo-alk-positive-nsclc-brain- metastases
4 Apr 2016 ... Earlier results from the ongoing PROFILE 1014 trial showed that crizotinib offers
better progression-free survival (PFS) and response rates ...

Pfizer Inc. - Pfizer Presents Overall Survival Data of XALKORI in ...

https://investors.pfizer.com/investor.../default.aspx
11 Sep 2017 ...PROFILE 1014 has provided important new data for patients with non-small cell
lung cancer," said Professor Tony Mok , Chair of Department ...

Crizotinib Crosses Another Finish Line in Lung Cancer - The ASCO ...

www.ascopost.com/.../crizotinib-crosses-another-finish-line-in-lung-cancer/
10 Mar 2015 ... Perhaps not surprising, the PROFILE 1014 investigators did not observe
differences in overall survival among ALK-positive patients receiving ...

PROFILE 1014 – Cancer Commons

https://www.cancercommons.org/tag/profile-1014/
4 Apr 2016 ... “Earlier results from the ongoing PROFILE 1014 trial showed that crizotinib offers
better progression-free survival (PFS) and response rates ...

LBA50Overall survival (OS) for first-line crizotinib versus ...

https://academic.oup.com/.../LBA50Overall-survival-OS-for-firstline- crizotinib
18 Sep 2017 ... LBA50Overall survival (OS) for first-line crizotinib versus chemotherapy in ALK+
lung cancer: Updated results from PROFILE 1014. T.S.K. Mok.

Pfizer Reports Positive Phase 3 Study Outcome Of XALKORI ...

www.pfizer.com/.../pfizer_reports_positive_phase_3_study_outcome_of_ xalkori_crizotinib_compared_to_chemotherapy_in_previously_untr...
25 Mar 2014 ... Pfizer Inc. announced today that PROFILE 1014, a Phase 3 study of anaplastic
lymphoma kinase (ALK) inhibitor XALKORI (crizotinib), met its ...

[PDF] 

Intracranial efficacy of crizotinib versus chemotherapy in PROFILE ...

tcr.amegroups.com/article/viewFile/9463/pdf
Intracranial efficacy of crizotinib versus chemotherapy in PROFILE. 1014: shining
a light on central nervous system endpoints in clinical trials. Terry L. Ng, D.

Results from PROFILE 1014: First-Line Crizotinib Versus ...

www.valuebasedcancer.com/.../results-from-profile-1014-first-line-crizotinib- versus-pemetrexed-platinum-in-alk-nsclc/
The PROFILE 1014 study was a phase 3, randomized study of 343 patients with
previously untreated, advanced, nonsquamous ALK+ NSCLC in which the ...

Intracranial Efficacy of Crizotinib for Patients with ALK-Positive Lung ...

www.jwatch.org/.../intracranial-efficacy-crizotinib-patients-with-alk
11 Apr 2016 ... To evaluate the use of crizotinib in this setting, investigators conducted an
industry-supported, single-arm, phase III trial (PROFILE 1014), ...

[PDF] 

175P: ALK positive lung cancer: Clinical profile and outcomes in a ...

www.jto.org/article/S1556-0864(16)30285-4/pdf
1 Apr 2016 ... (PROFILE 1014; NCT01154140) ALK+ advanced NSCLC. Methods: The
incidence of AEs associated with the clustered term. 'cardiac failure' ...

Profile 1014 trial shows overall survivaL data for Xalkori (crizotinib ...

https://www.epgonline.org/.../profile-1014-trial-shows-overall-survival-data- for-xalkori--crizotinib--in-previously-untreated-patients-with-alk-po...
15 Sep 2017 ... Pfizer Inc. announced final overall survival (OS) data from the PROFILE 1014 trial
examining Xalkori (crizotinib) in previously untreated patients ...

PROFILE 1014: lessons for the new era of lung ... - Europe PMC

europepmc.org/abstract/med/26629438
Abstract: PROFILE 1014 compared crizotinib to up to six cycles of standard
platinum-pemetrexed chemotherapy as the first line treatment of advanced...

[PDF] 

PROFILE 1014

www.txrating.org/texify/texify.aspx?trial=64
Analyse mthodologique de l'essai PROFILE 1014. TxRating.org. PROFILE 1014
crizotinib versus chemotherapy dans le cancer du poumon. Rsultats.

PROFILE 1014, 2014 trial summary - Trial Results Center

www.trialresultscenter.org/evidenceTable/viewTrial.aspx?trial...
Description and results of PROFILE 1014, 2014 clinical trial comparing crizotinib
versus chemotherapy in lung cancer (metastatic)

Searching for new agents against lung cancer: the PROFILE 1014 ...

https://www.youtube.com/watch?v=NptYxFhDs3g28 Sep 2017 - 3 min - Uploaded by VJOncology
Luis Paz-Ares, MD, from The University Hospital 12 de Octubre, Madrid, Spain speaks to us to ...

PROFILE 1014: Xalkori Prolongs NSCLC Survival - Cancer Therapy ...

www.cancertherapyadvisor.com/lung.../profile-1014.../339630/
25 Mar 2014 ... Pfizer announced results from PROFILE 1014, a Phase 3 study of Xalkori (
crizotinib) in previously untreated patients with anaplastic lymphoma ...

ESMO 2014: New Data on First- and Second-Line ALK Inhibition in ...

www.esmo.org/.../ESMO-2014-New-Data-on-First-and-Second-Line-ALK- Inhibition-in-NSCLC-Patients
6 Oct 2014 ... Overall and intracranial efficacy results and time to symptom deterioration in the
PROFILE 1014 study; Alectinib's activity in crizotinib ...

Overall Survival (OS) for First-Line Crizotinib Versus Chemotherapy ...

oncologypro.esmo.org/.../Overall-Survival-OS-for-First-Line-Crizotinib- Versus-Chemotherapy-in-ALK-Lung-Cancer-Updated-Results-from...
11 Sep 2017 ... LBA50 - Overall Survival (OS) for First-Line Crizotinib Versus Chemotherapy in
ALK+ Lung Cancer: Updated Results from PROFILE 1014 ...

Is there a progression-free survival benefit of first-line crizotinib ...

onlinelibrary.wiley.com/doi/10.1002/cam4.659/full
16 Feb 2016 ... More recently, in a phase 3 study (PROFILE 1014) comparing first-line crizotinib
with first-line pemetrexed plus platinum chemotherapy, the ...

Ceritinib as First-Line Treatment Option for ALK-Positive Advanced ...

www.primeoncology.org/primelines/ceritinib-alk-positive-nsclc/
29 Jun 2017 ... ... both in comparison to chemotherapy and compared to previously reported
PROFILE 1014 results with first-line crizotinib. However, he noted ...

Insight on Profile 1014: Phase III Study for Xalkori - Market Realist

marketrealist.com/.../insight-profile-1014-phase-iii-study-xalkori/
30 Nov 2015 ... Profile 1014 is the Phase III study for Xalkori, an ALK inhibitor. As per Pfizer's
press release, study was a randomized, and involved 343 ...

Moving molecularly directed therapies to the first-line in ALK-positive ...

pubmedcentralcanada.ca/pmcc/articles/PMC4630509/
The phase III PROFILE 1014 represents the culmination of the rapid development
of crizotinib and provides lessons for future generation ALK inhibitors and ...

Targeted Therapies in Oncology, Second Edition - Google Books Result

profile 1014

profile 1014

profile 1014

profile 1014

profile - 1014,profile - 1014,profile - 1014,profile - 1014,profile - 1014,profile - 1014,profile + 1014,profile + 1014,profile + 1014,profile + 1014,profile + 1014,profile + 1014,profile . 1014,profile . 1014,profile . 1014,profile . 1014,profile . 1014,profile . 1014,profile , 1014,profile , 1014,profile , 1014,profile , 1014,profile , 1014,profile , 1014,profile * 1014,profile * 1014,profile * 1014,profile * 1014,profile * 1014,profile * 1014,

profile 1014 , profile 1014 , profile 1014 , profile 1014 , profile 1014 , profile 1014 , profile 1014 , profile 1014 , profile - 1014,profile - 1014,profile - 1014,profile - 1014,profile - 1014,profile - 1014,profile + 1014,profile + 1014,profile + 1014,profile + 1014,profile + 1014,profile + 1014,profile . 1014,profile . 1014,profile . 1014,profile . 1014,profile . 1014,profile . 1014,profile , 1014,profile , 1014,profile , 1014,profile , 1014,profile , 1014,profile , 1014,profile * 1014,profile * 1014,profile * 1014,profile * 1014,profile * 1014,profile * 1014,profile 1014 , profile 1014 , profile 1014 , profile 1014 , profile 1014 , profile 1014 , profile 1014 , profile 1014 ,

profile - 1014,profile - 1014,profile - 1014,profile - 1014,profile - 1014,profile - 1014,profile + 1014,profile + 1014,profile + 1014,profile + 1014,profile + 1014,profile + 1014,profile . 1014,profile . 1014,profile . 1014,profile . 1014,profile . 1014,profile . 1014,profile , 1014,profile , 1014,profile , 1014,profile , 1014,profile , 1014,profile , 1014,profile * 1014,profile * 1014,profile * 1014,profile * 1014,profile * 1014,profile * 1014,

profile - 1014,profile - 1014,profile - 1014,profile - 1014,profile - 1014,profile - 1014,profile + 1014,profile + 1014,profile + 1014,profile + 1014,profile + 1014,profile + 1014,profile 1014 , profile 1014 , profile 1014 , profile 1014 , profile 1014 , profile 1014 , profile 1014 , profile 1014 , profile 1014 , profile 1014 , profile 1014 , profile 1014 , profile . 1014,profile . 1014,profile . 1014,profile . 1014,profile . 1014,profile . 1014,profile , 1014,profile , 1014,profile , 1014,profile , 1014,profile , 1014,profile , 1014,profile * 1014,profile * 1014,profile * 1014,profile * 1014,profile * 1014,profile * 1014,